OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Hwu on the Uptake of Cellular Therapy in Oncology

February 2nd 2021

Patrick Hwu, MD, discusses the uptake of cellular therapy in the treatment of patients with cancer.

Dr. Shitara on Analyzing the Effects of Prior Therapy on TAS-102 in Gastric/GEJ Cancer

February 2nd 2021

Kohei Shitara, MD, discusses the rationale to analyze the effects of prior therapy on outcomes with TAS-102 in patients with metastatic gastric/gastroesophageal junction cancer.

Dr. Campbell on the Importance of Multidisciplinary Care in RCC

February 1st 2021

Matthew T. Campbell, MD, MS, discusses the importance of utilizing a multidisciplinary treatment approach in renal cell carcinoma.

Dr. Spigel Discusses Advances in Early-Stage Lung Cancer

February 1st 2021

David Spigel, MD, discusses advances in early-stage lung cancer treatment.

Dr. McKenzie on the Rationale for Concurrent Tissue and Liquid Biopsies in Lung Cancer

February 1st 2021

Andrew McKenzie, PhD, discusses the rationale to utilize concurrent tissue- and liquid-based biopsies in lung cancer.

Dr. Murphy on the Utility of Pazopanib Plus SBRT in Pediatric Sarcoma

January 29th 2021

Erin Murphy, MD, discusses the utility of pazopanib plus stereotactic body radiation therapy in pediatric sarcoma.

Dr. Howard Sharp on the Importance of Racial and Ethnic Diversity in Pediatric Clinical Trials

January 29th 2021

Katianne M. Howard Sharp, PhD, discusses the importance of racial and ethnic diversity in clinical trials for pediatric patients with cancer.

Dr. Moore on the Use of Preventive Anastrozole Versus Tamoxifen in DCIS

January 28th 2021

Halle Moore, MD, discusses the use of preventive anastrozole versus tamoxifen in ductal carcinoma in situ.

Dr. Matsen on the Effects of Decreased Breast Cancer Screening in the COVID-19 Era

January 28th 2021

Cindy B. Matsen, MD, discusses the potential effects of the decrease in screening for patients with breast cancer during the coronavirus disease 2019 pandemic.

Dr. Callander on the Expanding Role of Belantamab Mafodotin in Multiple Myeloma

January 28th 2021

Natalie S. Callander, MD, discusses the expanding role of belantamab mafodotin-blmf in multiple myeloma.

Dr. Kumar on Treatment Selection Considerations in Multiple Myeloma

January 27th 2021

Shaji K. Kumar, MD, discusses treatment selection considerations in multiple myeloma.

Dr. Fonseca on the Shift Toward Frontline Quadruplet Regimens in Multiple Myeloma

January 26th 2021

Rafael Fonseca, MD, discusses the shift toward frontline quadruplet regimens in multiple myeloma.

Dr. Ailawadhi on Potential Combination Strategies in Multiple Myeloma

January 26th 2021

Sikander Ailawadhi, MD, discusses potential combination strategies with selinexor and belantamab mafodotin-blmf in multiple myeloma.

Dr. Ohri on the Role of Chemoradiation in Locally Advanced NSCLC

January 26th 2021

Nitin Ohri, MD, discusses the role of chemoradiation therapy in locally advanced non–small cell lung cancer.

Dr. Harismendy on the Challenges Faced With Molecular Testing in DCIS

January 25th 2021

Olivier Harismendy, PhD, discusses the challenge of molecular testing in patients with ductal carcinoma in situ.

Dr. Marshall on Changes With Adjuvant Treatment in CRC

January 25th 2021

John L. Marshall, MD, discusses recent changes to the adjuvant treatment landscape in colorectal cancer.

Dr. Strickler on Dosing Regorafenib in CRC

January 25th 2021

John H. Strickler, MD, discusses dosing strategies with regorafenib in colorectal cancer.

Dr. Dasari on the Potential Clinical Implications of Fruquintinib in mCRC

January 25th 2021

Nageshwara Arvind Dasari, MD, discusses the potential clinical implications with fruquintinib in metastatic colorectal cancer.

Dr. Callander on Selecting a Frontline Treatment Strategy in Multiple Myeloma

January 22nd 2021

Natalie S. Callander, MD, discusses selecting a frontline treatment strategy for patients with multiple myeloma.

Dr. Ciombor on the FDA Approval of Trastuzumab Deruxtecan in HER2+ Metastatic Gastric Cancer

January 22nd 2021

Kristen K. Ciombor, MD, MSCI, discusses the FDA approval of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic gastric cancer.